MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety

Allergy and Asthma Proceedings

Volumn 33, Issue 4, 2012, Pages 324-332

  Meltzer, Eli O ^a   LaForce, Craig ^b   Ratner, Paul ^c   Price, David ^d   Ginsberg, David ^e   Carr, Warner ^f  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b North Carolina Research Center   (United States)

^c Sylvana Research Associates   (United States)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e Meda Pharmaceuticals   (United States)

^f Allergy & Asthma Associates of Southern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; FLUTICASONE PROPIONATE; MP 29 02; NOSE SPRAY; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; EPIPHORA; EPISTAXIS; FEMALE; FEVER; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NASAL PRURITUS; NAUSEA; NOSE CONGESTION; OROPHARYNX PAIN; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; REFLECTIVE TOTAL NASAL SYMPTOM SCORE; REFLECTIVE TOTAL OCULAR SYMPTOM SCORE; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; RHINOPHARYNGITIS; RHINORRHEA; SCHOOL CHILD; SCORING SYSTEM; SNEEZING; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHTHALAZINES; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864753109     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3587     Document Type: Article

References (32)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122(suppl):S1-S84, 2008. (Pubitemid 352033573)
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
3. Dalal AA, Stanford R, Henry H, and Borah B. Economic burden of rhinitis in managed care: A retrospective claims data analysis. Ann Allergy Asthma Immunol 101:23-29, 2008. (Pubitemid 352000740)
4. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 29:600-608, 2008.
5. Reed SD, Lee TA, and McCrory DC. The economic burden of allergic rhinitis: A critical evaluation of the literature. Pharmacoeconomics 22:345-361, 2004. (Pubitemid 38609812)
6. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 31:375-380, 2010.
7. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 62(suppl 85):9-16, 2007. (Pubitemid 47561568)
8. Physician Survey Sponsored by the American College of Allergy, Asthma and Immunology. Rochester, NY: Harris Interactive, Inc., October 19-21, 2001.
9. Meltzer EO, and Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 106(suppl):S12-S16, 2011.
10. Patel P, D'Andrea C, and Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 21:499-503, 2007. (Pubitemid 47360041)
11. Nielsen LP, and Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: A review of randomized, controlled trials. Am J Respir Med 2:55-65, 2003. (Pubitemid 37062717)
12. Akerlund A, Andersson M, Leflein J, et al. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medications. J Allergy Clin Immunol 115:S460-S482, 2005. (Pubitemid 40320996)
13. Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 105:168-173, 2010.
14. Juniper EF, and Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21:77-83, 1991.
15. Guidance for Industry, E6 Good Clinical Practice: Consolidated Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 1-17, April 1996, ICH.
16. Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for Drug Products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD, 1-58, April 2000.
17. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:74-81, 2008.
18. Juniper EF, Guyatt GH, Griffith LE, and Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98:843-845, 1996. (Pubitemid 26357253)
19. HealthSTAR Communications in partnership with Schulman, Ronca & Bucuvales, Inc., Allergies in America: A Landmark Survey of Nasal Allergy Sufferers. Available online at www.mmcpub.com/scsaia/adult.pdf; accessed June 24, 2010.
20. Maurer M, and Zuberbier T. Undertreatment of rhinitis symptoms in Europe: Findings from a cross-sectional questionnaire survey. Allergy 62:1057-1063, 2007. (Pubitemid 47220961)
21. Valvorita E, Myrseth S, and Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol 8:1-9, 2008.
22. Loh CY, Chao SS, Chan YH, and Wang DY. A clinical survey on compliance in the treatment of rhinitis using nasal steroids. Allergy 59:1168-1172, 2004. (Pubitemid 39389470)
23. Demoly P, Allaert F-A, Lescable M, and PRAGMA. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy 57:546-554, 2002.
24. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 129:1282-1289, 2012.
25. Bukstein D, Luskin AT, and Farrar JR. The reality of adherence to rhinitis treatment: Identifying and overcoming barriers. Allergy Asthma Proc 32:265-271, 2011.
26. Tomooka LT, Murphy C, and Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 110:1189-1193, 2000. (Pubitemid 30439780)
27. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 100:272-279, 2008. (Pubitemid 351398007)
28. Keith PK, and Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin 25:2021-3041, 2009.
29. Naclerio RM, Pinto J, deTineo M, and Baroody FM. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc 29:24-28, 2008.
30. Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 100:194-199, 2008. (Pubitemid 351397996)
31. Bousquet J, Knani J, Dhivert H, et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 149:371-375, 1994.
32. Meda Pharmaceuticals, Inc. Dymista package insert. Somerset, NJ; April 2012.